Clinical Trials Browser

Phase 1 × Has announcements × daratumumab × Clear all

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1 Completed

240 enrolled 2 FDA

Multiple Myeloma